Lifeward shares rise 25.45% intraday after Humana Medicare Advantage Plan approves ReWalk 7 reimbursement.

Lifeward (LFWD) surged 25.45% intraday following the announcement that Humana Medicare Advantage Plan granted prior authorization for its ReWalk 7 Personal Exoskeleton. This marks the second major Medicare Advantage provider—after UnitedHealthcare—to approve reimbursement, covering 47% of U.S. Medicare Advantage enrollees. The CEO highlighted the milestone as a critical step in payer adoption, enhancing access to the technology for spinal cord injury patients and strengthening Lifeward’s revenue and cash flow potential. The news directly aligns with the stock’s upward movement, as expanded reimbursement pathways signal growing market acceptance and scalable growth opportunities. Sector-wide healthcare tech momentum may have amplified the rally, but the company-specific authorization from Humana, a leading Medicare provider, was the primary catalyst.